BeOne Medicines (ONC) Stock Price, Quote, News & History | Benzinga

SPY763.95−0.01%QQQ741.84−0.03%BTC/USD84,530.59+1.17%DIA508.60−0.00%GLD382.40−0.09%TLT77.72+0.01%

BeOne Medicines Ltd (ONC) Stock Price, Quote, News & History

ONCNASDAQ

Trade with Public

Trade with Public

$358.77

-7.17-1.96%

Last update: Oct 1, 4:28 PM

$358.77

-7.17-1.96%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$367.94

Close

$358.77

Volume / Avg.

348.36K / 387.10K

Day Range

$358.32 - $371.09

52 Wk Range

253.95 - 385.22

Market Cap

$40.58B

P/E Ratio

65.46

Dividend Yield

-

Exchange

NASDAQ

RSI

51

Short Interest

2.12%

Days to Cover

4.51

Recent BeOne Medicines AG News

Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President

Trump secures drug pricing deals with nine pharma companies as Kennedy reveals intense pressure from the President to deliver.

Namrata Sen

Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens

FDA approves Jazz Pharmaceuticals' Ziihera combinations for first-line treatment of HER2-positive gastroesophageal adenocarcinoma.

Vandana Singh

BeOne Medicines Advances Chemotherapy-Free Lymphoma Strategy

BeOne Medicines reported positive Phase 3 BRUKINSA data in mantle cell lymphoma, reducing progression or death risk by 43% ahead of planned filings.

Vandana Singh

What's Going On With Summit Therapeutics Stock On Monday?

Summit Therapeutics' new ivonescimab trial results showed a survival benefit in lung cancer and encouraging data in colorectal cancer.

Vandana Singh

BeOne Medicines: Recent FDA Approval Rewrites One-Drug Narrative

Bamboo Works

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

1.48B

Investing Cash Flow (TTM)

-182.47M

Financing Cash Flow (TTM)

1.12B

Free Cash Flow (TTM)

1.31B

Capital Expenditure (TTM)

-175.08M

Net Change in Cash (TTM)

2.42B

Analyst Trends and Forecast

5

Jul

5

Aug

1

Sep

1

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$39.52B

PE Ratio (TTM)

65.46

PE Ratio (FWD)

35.34

PEG Ratio (TTM)

0.77

PS Ratio (TTM)

6.89

PB Ratio (TTM)

8.00

Earnings Yield % (TTM)

1.53%

Earnings Yield % (FWD)

2.83%

EV / EBITDA (TTM)

34.70

Price / EBITDA (TTM)

37.08

Price / Free Cash Flow (TTM)

32.27

Book Value / Share

$45.74

Company Debt

Total Debt

$1.07B

LT Debt

$882.16M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$43.57M

Total Cash

$5.10B

Debt to Equity

0.22

Issuance of Debt (TTM)

$807.01M

Repayment of Debt (TTM)

-$812.57M